Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Sitaxentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms SR-PAAS
- Sponsors Pfizer
- 12 May 2014 New trial record
- 18 Apr 2011
- 14 Mar 2011